Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lacticaseibacillus Rhamnosus LRa05 for Alleviating Allergic Rhinitis
Sponsor: Wecare Probiotics Co., Ltd.
Summary
This clinical trial aims to evaluate the efficacy and safety of Lactobacillus rhamnosus LRa05 in alleviating allergic rhinitis symptoms and its effects on gut microbiota in 70 adults aged 18-60 years. Participants will receive probiotic powder or placebo daily for 4 weeks. Allergic rhinitis symptoms and quality of life will be assessed, while stool and blood samples will be collected to evaluate changes in gut microbiota and immune-related markers.
Official title: Effectiveness of Lacticaseibacillus Rhamnosus LRa05 in Alleviating Allergic Rhinitis and Its Impact on Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2024-12-01
Completion Date
2026-05-01
Last Updated
2026-10-19
Healthy Volunteers
Yes
Conditions
Interventions
probiotic product
During the study, subjects take one sachet of Lactobacillus rhamnosus LRa05 daily. Evaluation is conducted by monitoring the subjects' nasal symptoms and gut microbiota before and after the intervention.
Maltodextrin
During the study, subjects in the control group take one sachet of maltodextrin daily. Evaluation is conducted by monitoring the subjects' nasal symptoms and gut microbiota before and after the 8-week trial.
Locations (1)
Qilu Hospital of Shangdong University
Jinan, Shangdong, China